Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -74.48% is 100% above its 5-year average of -24064.76%, near the high end of its 5-year range (-143379.86%–14.69%).
64.35% above its 12-month average of -208.94%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -20.69%.
RETURN ON ASSETS (ROA)
-74.48%
RETURN ON ASSETS (ROA) AVG TTM
-208.94%
RETURN ON ASSETS (ROA) AVG 3Y
-35981.57%
RETURN ON ASSETS (ROA) AVG 5Y
-24064.76%
RETURN ON ASSETS (ROA) AVG 10Y
-13237.80%
RETURN ON ASSETS (ROA) AVG 15Y
-319.58%
RETURN ON ASSETS (ROA) AVG 20Y
-247.63%
CURRENT VS TTM AVG
+64.35%
CURRENT VS 3Y AVG
+99.79%
CURRENT VS 5Y AVG
+99.69%
CURRENT VS 10Y AVG
+99.44%
CURRENT VS 15Y AVG
+76.69%
CURRENT VS 20Y AVG
+69.92%
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-131.02%
vs the sector median at left
ProMIS Neurosciences, Inc.
Market Cap
$82.59M
Return on Assets (ROA)
-74.48%
TTM Avg
-208.94%
3Y Avg
-35981.57%
5Y Avg
-24064.76%
Market Cap
$84.13M
Return on Assets (ROA)
-43.13%
TTM Avg
-80.45%
3Y Avg
-58.18%
5Y Avg
-65.67%
Market Cap
$82.47M
Return on Assets (ROA)
-107.29%
TTM Avg
-60.42%
3Y Avg
-51.23%
5Y Avg
-39.69%
Market Cap
$82.53M
Return on Assets (ROA)
-109.51%
TTM Avg
-695.26%
3Y Avg
-854.30%
5Y Avg
-733.67%
Market Cap
$81.22M
Return on Assets (ROA)
-26.59%
TTM Avg
-23.05%
3Y Avg
-19.50%
5Y Avg
-17.99%
Market Cap
$82.29M
Return on Assets (ROA)
49.88%
TTM Avg
-47.68%
3Y Avg
-37.92%
5Y Avg
-34.36%
Market Cap
$81.20M
Return on Assets (ROA)
-110.64%
TTM Avg
-124.68%
3Y Avg
-93.30%
5Y Avg
-78.61%
Market Cap
$85.86M
Return on Assets (ROA)
-91.66%
TTM Avg
-48.70%
3Y Avg
-37.97%
5Y Avg
-29.79%
Market Cap
$80.30M
Return on Assets (ROA)
-70.05%
TTM Avg
-71.47%
3Y Avg
-58.80%
5Y Avg
-51.13%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ProMIS Neurosciences, Inc. (PMN) | $82.59M | -74.48% | -208.94% | -35981.57% | -24064.76% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.13M | -43.13% | -80.45% | -58.18% | -65.67% |
| Cardiff Oncology, Inc. (CRDF)vs › | $82.47M | -107.29% | -60.42% | -51.23% | -39.69% |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)vs › | $82.53M | -109.51% | -695.26% | -854.30% | -733.67% |
| MediciNova, Inc. (MNOV)vs › | $81.22M | -26.59% | -23.05% | -19.50% | -17.99% |
| LENSAR Inc (LNSR)vs › | $82.29M | 49.88% | -47.68% | -37.92% | -34.36% |
| Nutriband Inc. (NTRB)vs › | $81.20M | -110.64% | -124.68% | -93.30% | -78.61% |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $85.86M | -91.66% | -48.70% | -37.97% | -29.79% |
| Humacyte, Inc. (HUMA)vs › | $80.30M | -70.05% | -71.47% | -58.80% | -51.13% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $86.32M | -79.38% | 41.63% | -36.06% | -44.84% |
ROA
-74.5%
ROE
-85.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -432.56% |
| 2024-12-31 | 14.69% |
| 2023-12-31 | -128.54% |
| 2022-12-31 | -143379.86% |
| 2021-12-31 | -53.38% |
| 2020-12-31 | -408.88% |
| 2019-12-31 | -356.68% |
| 2018-12-31 | -251.67% |
| 2017-12-31 | -220.53% |
| 2016-12-31 | -265.59% |
| 2015-12-31 | -132.82% |
| 2014-03-31 | -692.10% |
| 2013-03-31 | -644.51% |
| 2012-03-31 | -703.68% |
| 2011-03-31 | -197.81% |
| 2010-03-31 | -94.38% |
| 2009-03-31 | -103.02% |
| 2008-03-31 | -105.06% |
| 2007-03-31 | -62.67% |
| 2006-03-31 | -78.78% |
| 2006-03-31 | -34.62% |
| 2005-03-31 | -26.35% |
